Celltrion Holdings, the holding company of the Celltrion Group, announced on the 10th that it will proceed with an additional purchase of Celltrion shares worth 338.2 billion won. In July, Holdings had unveiled a large-scale plan to purchase Celltrion shares to improve profitability and enhance the value of its subsidiaries. As of last month, the Celltrion shares purchased by Holdings this year have amounted to 535.9 billion won. Including this newly announced additional purchase, the total purchase amount of Celltrion shares by Holdings for this year will reach 874.1 billion won.
This decision to acquire additional shares reflects an investment judgment that highly regards Celltrion’s growth potential. Particularly, through bold investments in subsidiaries that are undervalued compared to their intrinsic values, the company aims to enhance shareholder value and secure profitability by expanding its stake, anticipating increased compensation.
Efforts to enhance shareholder value at Celltrion are being implemented across the entire group, including the major shareholders. The subsidiary, Celltrion, has repurchased its own shares worth around 850 billion won over nine occasions this year alone and has canceled shares worth 900 billion won. Additionally, Seo Jung-jin, chairman of the Celltrion Group, purchased Celltrion shares worth about 50 billion won in July, while the affiliate, Celltrion Skincure, bought shares worth approximately the same amount. Celltrion employees also participated by purchasing around 40 billion won worth of employee stock ownership.
With the completion of Holdings’ additional share acquisition announced on this day, the group will have purchased Celltrion shares worth 1.85 trillion won this year alone. Holdings believes that, given Celltrion’s clear performance growth, the company will soon be appropriately valued by the market.
In the future, if the market stabilizes, Holdings plans to decide the timing for selling the newly acquired shares in the second half of this year in a manner that minimizes market burden, aiming for business structure reorganization and capital efficiency for the holding company. A representative from Celltrion Group stated, “The temporary profit pressure factors from the merger process are expected to be reflected and mostly resolved by the third and fourth quarters of 2025,” adding, “This acquisition is likely to be the final phase.”